Cooperative Human Tissue Network (CHTN) (UM1 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

 The purpose of this Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), is to support the Cooperative Human Tissue Network (CHTN). The goal for CHTN is to collect and distribute to investigators high quality human tissue specimens to facilitate basic and early translational cancer research. For example, such specimens may be needed for scientific discovery and the development of various molecular diagnostic tests, prognostic or predictive assays. The CHTN is designed as a unique biospecimen resource in that it is based on prospective collection and distribution of samples upon specific investigators' requests. Samples to be collected from patients include pre-cancerous, cancerous, and benign neoplastic tissues, as well as specimens corresponding to non-neoplastic diseases and uninvolved tissues.

This FOA solicits applications for CHTN awards from institutions/teams capable of contributing to the mission of CHTN by: (1) providing prospective investigator-defined procurement of high-quality malignant, benign, diseased, and uninvolved (normal adjacent) tissues and fluids from patients throughout North America and elsewhere; (2) assisting individual investigators with regard to specific specimen needs of their research; (3) assisting in developing and disseminating knowledge on high quality practices for successfully operating a biospecimen repository; and (4) educating the community about the importance of the availability of high quality human tissue specimens for medical research. Depending on their intentions and capabilities, applicants must indicate whether they propose to function as the CHTN adult biospecimen division or the pediatric specimen division. Nonetheless, it will be acceptable for an adult biospecimen division, if capable, to contribute pediatric samples for networked requests.

Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed. 


  • Duke Internal Deadline: July 18, 2018
  • Letter of Intent Due Date(s): July 28, 2018
  • Application Due Date(s): August 28, 2018

RFA-CA-18-025 Expiration Date August 29, 2018

If the internal deadline has passed and you are interested in this opportunity, please email Anastasia Maddox at to find out if it is still open.

Agency Website

Eligibility Requirements

 Any individual designated as the PD/PI for the proposed CHTN Division must be a board-certified anatomical and/or surgical pathologist, who is actively involved in the operation of a pathology laboratory that has demonstrated access to human cancer tissues.

Applicants are encouraged to consider designating a single PD/PI located at the application-submitting institution (i.e., Primary Institution). If multiple PDs/PIs are designated, all of them must be affiliated with the application-submitting institution.



    Amount Description

     Budget requests must not exceed $800,000 in direct costs per year. However, all application budgets must reflect the actual needs of the proposed Division. It is expected that maximal allowable budget will be requested only when justified by particularly broad scope of activities whereas other applications will have smaller budget requests.

     All applicants must request a project period of 5 years.

      Funding Type





      Environmental & Life Sciences
      Medical - Basic Science
      Medical - Clinical Science

      Internal Nomination

      Owing to the sponsor's restriction on the number of applications that may be submitted from Duke, anyone wishing to pursue nomination should submit the following materials as one PDF.

      * A letter of support from dean or chair - 1 to 1.5 pages
      * Project summary - 2 to 4 pages
      * CV or Biosketch of project leader

      Please submit internal materials through My Research Proposal. (Code ILN)

      Instructions for setting up your account and uploading internal applications can be found here:

      Internal Deadline

      July 18, 2018

      External Deadline

      August 28, 2018